Cima Universidad de Navarra 20
2.2. Publicaciones Destacadas de 2019 Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and lowdose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Attal, M. et al. Lancet. 2019 Dec 7;394(10214):2096-2107. Programa de Hemato-oncología Factor de impacto: 60.392 Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. PerezRuiz, E. et al. Nature. 2019 May;569(7756):428-432. Programa de Inmunología e Inmunoterapia Factor de impacto: 42.778 Dynamics and genomic landscape of CD8(+) T cells undergoing hepatic priming. Benechet, AP. et al. Nature 2019. Oct;574(7777):200-205. Programa de Terapia génica y regulación de la expresión génica Factor de impacto: 42.778 Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson, PG. et al. Lancet Oncology 2019. Jun;20(6):781-794. Programa de Hemato-oncología Factor de impacto 33.752
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Segovia, C. et al. Nature Medicine 2019. Jul;25(7):10731081. Programa de Hemato-oncología Factor de impacto 36.130 Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Melero I et al. Nature Medicine 2019. Mar;25(3):470-476. Programa de Inmunología e Inmunoterapia Factor de impacto 36.130 Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Swarup, V. et al. Nature Medicine 2019. Jan;25(1):152-164. Programa de Neurociencias Factor de impacto 36.130 Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma. Kim, JW. et al. Nature Medicine 2019. Nov;25(11):1783-1795. Programa de Tumores Sólidos Factor de impacto 36.130 Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation. Berraondo, P. et al. Cancer Discovery 2019. Aug;9(8):10031005 Editorial Material. Programa de Inmunología e Inmunoterapia Factor de impacto 29.497
